OraSure Technologies Inc., the rapid medical diagnostics company based in Bethlehem, reported net income of $3.8 million or 7 cents a share in the second quarter.
The company’s consolidated net revenue of $31.4 million was up 3 percent from the same quarter last year.
“We are pleased with the company’s financial performance for the second quarter of 2016, which exceeded expectations on both the top and bottom lines,” Douglas A. Michels, president and CEO of OraSure Technologies, said in a statement.
“Continued growth in sales of our infectious disease and molecular collection systems products were the main drivers behind this performance,” he said.
“We expect long-term growth from both of these businesses and see the international marketplace as an emerging and increasingly important strategic priority for our company.”
OraSure makes OraQuick rapid tests for hepatitis, HIV and Ebola. The company is developing a rapid diagnostic test for the Zika virus.